Compare Global Payments Inc (GPN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Global Payments Inc trades at $82.44 (market cap $21.46B), while Regeneron Pharmaceuticals Inc trades at $745.87 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.5× Global Payments Inc's market cap, and Global Payments Inc pays the higher dividend (1.23%). Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| GPN | REGN | |
|---|---|---|
Market Cap | $21.46B | $76.14B |
Volume | 1,482,600 | 500,239 |
Sector | Financials | Health |
52-Week High | $94.83 | $852.03 |
52-Week Low | $62.47 | $557.73 |
Typical Hold Time | 50 Days | 107 Days |
Enterprise Value | $39.60B | $70.85B |
Dividend Yield | 1.23% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.20, up 1.38% on the day, with a neutral technical signal and bullish moving averages. The stock has beaten EPS estimates for three consecutive quarters, though Q3 2026 results are pending. Revenue declined to $7.71B in 2025, but net income margin improved to 18.16%. Analyst consensus is bullish with a $102.75 price target, representing significant upside. Recent news highlights growth initiatives like the Genius platform and Worldpay integration.
GPN offers potential upside based on strong analyst sentiment and strategic initiatives, but faces risks from rising costs, high debt levels, and competitive pressures. The negative net income margin projection for 2026 underscores execution challenges. Investors should weigh the company's digital payment growth against macroeconomic and operational headwinds.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
